ADDITIONAL INFORMATION CONTINUED EQUITY SECURITIES INFORMATION The Company has only one class of shares, being ordinary shares. Each ordinary share is entitled to one vote when a poll is called; otherwise on a show of hands at a shareholder meeting every member present in person or by proxy has one vote. There are no securities subject to escrow. On 2 December 2024, the Company commenced an on-market share buy-back program, The on-market share buy-back program has a buy-back period of up to 12 months and will not exceed 5% of the total shares on issue in Neuren as at the date 12 months prior to the commencement of the buy-back. The following information is based on share registry information processed up to and including 14 March 2025. The number of ordinary shareholdings held in less than marketable parcels at 14 March 2025 was 961, holding 21,790 ordinary shares. DISTRIBUTION OF SECURITY HOLDERS Listed ordinary shares Size of holding Number of ordinary shares % Number of holders % 100,001 and Over 87,748,126 69.31 124 1.07 10,001 to 100,000 24,100,242 19.04 827 7.13 5,001 to 10,000 5,064,985 4.00 680 5.87 1,001 to 5,000 7,358,815 5.81 2,999 25.87 1 to 1,000 2,323,853 1.84 6,963 60.06 Total 126,596,021 100.00 11,593 100.00 UNLISTED SECURITIES 1,950,000 Loan Funded Shares, held as treasury stock, with a weighted average exercise price of $1.84, with an expiry date of 13 July 2025. There are 2 holders of 100,001 and over. 1,360,000 Employee Share Scheme options, with a weighted average exercise price of $7.34, of which 650,000 have an expiry date of 3 February 2026, 450,000 have an expiry date of 8 July 2026 and 260,000 have an expiry date of 7 February 2029. There are 6 holders of 100,001 and over. Neuren Pharmaceuticals Limited Annual Report 2024 55
RkJQdWJsaXNoZXIy MjE2NDg3